中国社会科学院日前发布的《2012年中国药品市场报告》称，在我国药品市场上，外资药品已逐步占据优势地位。

Released by the Chinese academy of social sciences[In 2012, the Chinese medicine market report]said,In the pharmaceutical market in China,Foreign drug has gradually occupy a dominant position.

　　该报告由中国社科院公共政策经济研究中心历时3年调查完成。目前，二三级医院已经成为我国药品市场销量最重要的组成部分，国内外药业却也正经历着无声战。对比2006年到2011年间三级医院的药品供应企业的排序，专家发现，到2011年仍保持第一供应企业地位的仅有24.14%，这反映超过四分之三的企业失去了原有的优势地位。

The report by the Chinese academy of social sciences public policy center for economic research survey for 3 years.At present,,Two third-level hospital has become the most important component of China's pharmaceutical market sales,Pharmaceutical industry at home and abroad but also is experiencing silence.Contrast between 2006 and 2011 the third class hospitals of drug supply the order of the enterprise,Experts found,In 2011 to remain the first supply enterprise status of only 24.14%,It reflects more than three quarters of the enterprise lost their dominant position.

　　“我国三级医院药品竞争十分激烈，在医院保持最大供应商的地位十分困难。”在公共政策经济研究中心副主任程锦锥看来，这正是外资药企占领中国药品市场的一个演变过程。数据显示，当前我国药品市场中，外资企业在我国药品市场上占有优势地位。二级医院药品市场排名前5位的是辉瑞制药、赛诺菲、拜耳、扬子江药业和上药集团5家企业。其中，仅有两家民族企业；而三级医院药品市场中占有率排名前5位的制药企业：辉瑞、阿斯利康、赛诺菲、拜耳和罗氏均是外资企业，这意味着，外资企业在三级医院药品市场中更具优势。

"The third class hospitals in our country medicine competition is very fierce,It is very difficult to maintain the position of the biggest supplier in a hospital."In the public policy ChengJinZhui opinion, deputy director of the center for economic research,This is wholly foreign-owned enterprises occupy a evolution process of the Chinese pharmaceutical market.Data showed that,The current pharmaceutical market in China,The foreign capital enterprise in our country medicine occupy a dominant position in the market.2 class hospital pharmaceutical market is the top five were Pfizer/sanofi/bayer/Yangtze river pharmaceutical group and irrigation 5 companies.Among them,Only two national enterprise;And tertiary hospital drug in the market share of the top five of the pharmaceutical enterprises:Pfizer/astrazeneca/sanofi/Bayer and roche is foreign capital enterprise,This means that,The foreign capital enterprise in tertiary hospital drug more advantage in the market.

　　面对外资药业在三级医院的主导地位，民族药业的生存空间主要退回到二级医院中，但发展前景尚不乐观。程锦锥说，研究显示，外资企业正逐步向二级医院渗透，我国民族医药业的发展正受到一定的影响。(实习生宁迪)

In the face of foreign pharmaceutical industry in the leading role of the third class hospitals,National pharmaceutical living space of the main return to 2 class hospital,But the development prospect is not optimistic.ChengJinZhui said,Studies have shown that,The foreign capital enterprise is gradually to the second class hospitals,The development of China's national pharmaceutical is affected by a certain.(Interns NingDi)